Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T33917
(Former ID: TTDI01209)
|
|||||
Target Name |
Hydroxy radical elimination (HYRE)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Urinary system disease [ICD-11: GC2Z] | |||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | HD-003 | Drug Info | Phase 2 | Kidney disease | [2] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | HD-003 | Drug Info | [1] |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. | |||||
REF 2 | ClinicalTrials.gov (NCT02378194) Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.